| Name | Allergy Therapeutics |
|---|---|
| Epic | AGY |
| Isin | GB00B02LCQ05 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 7.60p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £362.25 | Debt ratio | n/a |
| Shares in issue | 4,766.44 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -106.52 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.07 | 52-week high / low | 2.00p / 8.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Allergy Therapeutics |
|---|---|
| Address | Dominion Way, Worthing, West Sussex, United Kingdom, BN14 8SA |
| Telephone | +44 (0) 1903 844 700 |
| Website | http://www.allergytherapeutics.com/ |
| Director | Position |
|---|---|
| Mr Manuel Llobet | CEO |
| Mr Anthony Parker | Non-Executive Director |
| Mr Cheryl MacDiarmid | Non-Executive Director |
| Mr David Ball | Non-Executive Director |
| Mr Zheqing Shen | Non-Executive Director |
| Mr Peter Jensen | Non-Executive Chairman |
| Mr Shaun Furlong | Chief Finance Officer |
| Dr Tunde Otulana | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
| Intangible asssets and goodwill | 4.69 | 5.14 | 5.04 |
| Investments and other non-current assets | 2.91 | 4.87 | 5.96 |
| Total non-current assets | 31.34 | 33.24 | 31.19 |
| Inventory / work in progress | 12.74 | 11.59 | 11.41 |
| Trade and other receivables | 7.82 | 7.09 | 10.47 |
| Cash and equivalents | 12.91 | 14.85 | 20.52 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 64.83 | 66.77 | 73.58 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 20.55 | 18.56 | 18.05 |
| Long term liabilities | 40.57 | 46.14 | 17.13 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 61.12 | 64.7 | 35.18 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 3.71 | 2.07 | 38.4 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 4.78 | 0.69 | 0.65 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -198.93 | -161.87 | -117.91 |
| Share premium account | 154.64 | 119.03 | 112.58 |
| Total equity | 3.71 | 2.07 | 38.4 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -35.26 | -39.65 | -12.24 |
| Pre-tax profit | -39.17 | -41.77 | -12.66 |